

Electronic Acknowledgement Receipt

EFS ID:	6526564
Application Number:	10576981
International Application Number:	
Confirmation Number:	8112
Title of Invention:	Method Of Therapy
First Named Inventor/Applicant Name:	Martin Leonard Ashdown
Customer Number:	22442
Filer:	Robert D. Traver/Lisa Behan
Filer Authorized By:	Robert D. Traver
Attorney Docket Number:	5517-18
Receipt Date:	25-NOV-2009
Filing Date:	02-MAR-2007
Time Stamp:	13:41:47
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	HRYNIEWICZ_CTLA_4_Blockage_decreases_2006.pdf	651165 498f57522ad01dcac0f1cd0f612b8ed981f714ae	no	10

Warnings:

Information:

2	NPL Documents	IMAMI_Clin_Exp_Immunol_1999.pdf	1252294	no	9
			243e001fedb00b711ac42807c482841251e7adce		
Warnings:					
Information:					
3	NPL Documents	IMAMI_Development_immunotherapeutic_2001.pdf	1494928	no	14
			b9e55db7ab39bd806df910cb0042bdaeda4eff1f		
Warnings:					
Information:					
4	NPL Documents	IWASHIRO_Immunosuppression_cd4_2001.pdf	797357	no	5
			043fb24202dfb90d8d217a482e71ca32dbf1f1b3		
Warnings:					
Information:					
5	NPL Documents	JONULEIT_Identification_functional_2001.pdf	659453	no	10
			b34a472be922df75c2e6815d459102ad9682c8b1		
Warnings:					
Information:					
6	NPL Documents	KANAI_J_Immunol_1996.pdf	1031943	no	7
			5b00a8e7905f8ee94381369e836e27277a3e23bf		
Warnings:					
Information:					
7	NPL Documents	KEIMOWITZ_Dementia_improvement_1997.pdf	615452	no	9
			b03e5c6ea8886254d5886882f86178c43aa4240e		
Warnings:					
Information:					
8	NPL Documents	KILBY_Recurrence_2000.pdf	157297	no	4
			12fdd542e07c63a7569490057aa7c9ed46262aee		
Warnings:					
Information:					
9	NPL Documents	KINTER_CD25_CD4_Regulatory_tcells_2004.pdf	1973316	no	13
			e31053f90437bccef11c5551d588b86f1efa219e		
Warnings:					
Information:					
10	NPL Documents	KINTER_Suppression_HIV_specific_2007.pdf	437374	no	6
			89de384f306ad08166345cf389a599373726a771		
Warnings:					
Information:					

11	NPL Documents	KNOECHEL_Sequential_development_2005.pdf	390805	no	12
			38bc486e85533bd62319b973e78a40871662849f		
Warnings:					
Information:					
12	NPL Documents	KOHM_CD4_CD25_Regulatory_2002.PDF	452170	no	5
			77155d283be9d8407b2988375db5d6e36e7a412f		
Warnings:					
Information:					
13	NPL Documents	KUKREJA_Autoimmunity_1999.pdf	1022389	no	15
			2a1e4eee303b14711596312fde48f1670a7aded6		
Warnings:					
Information:					
14	NPL Documents	LIANG_Murine_aids_1996.pdf	145957	no	1
			b2105fcb1de21a859adc66fa4b641b16dd18f860		
Warnings:					
Information:					
15	NPL Documents	LIFSON_Containment_simian_immunod.pdf	160725	no	10
			3322093a65b41f8151fa2a98eb9f6b831ff93ced		
Warnings:					
Information:					
16	NPL Documents	LIM_Cell_surfact_markers_2006.pdf	195356	no	7
			ffc39403788120f13046166935e3a09e1b973b0		
Warnings:					
Information:					
17	NPL Documents	LIM_Proportions_circulating_Tcells_2007_.pdf	808065	no	10
			11be464f305abfd3f73e7c5476d01e01cd341a79		
Warnings:					
Information:					
18	NPL Documents	LORI_Hydroxyurea_HIV_1999.pdf	913104	no	10
			c30d34be3ae68df9b59a3f25dff022bb75700aa		
Warnings:					
Information:					
19	NPL Documents	LORI_Targeting_HIV_reservoirs_1999.pdf	2312175	no	21
			57af74a1f7e40a97231327a1c5fc484be78c0db7		
Warnings:					
Information:					

20	NPL Documents	MAHMOUD_Role_C-Reactive_protein_2002.pdf	511651	no	6
			a1c8e511a7ca4e8a2b5d5a3fb6b7d2e03e77479		
Warnings:					
Information:					
21	NPL Documents	MASON_Expression_Norwalk_virus_1996.pdf	588131	no	6
			e053e66940ae42829c83788c53e9df2697e1e69d		
Warnings:					
Information:					
22	NPL Documents	MAURY_Comparative_study_serum.pdf	495882	no	8
			5fee97a9117c1112e9cf3740e49387072ec1bd8		
Warnings:					
Information:					
23	NPL Documents	MCGUIRK_Pathogen_shift_2.pdf	696661	no	6
			49cc8627da44842ec71a98096dbb92918fe9b17		
Warnings:					
Information:					
24	NPL Documents	MCMILLAN_Prospective_study_circulating_tlymphocyte_1997.pdf	560752	no	4
			c8d2282d8f58bc0d80e40b8d58d879cc982c146a		
Warnings:					
Information:					
25	NPL Documents	MCMILLAN_Prospective_study_tumor_recurrence_1995.pdf	641957	no	4
			d6b5dbcb72120fc6bc1ac71d79aaad9210e9eae		
Warnings:					
Information:					
26	NPL Documents	Medline_abstract_AVERSA_1999.PDF	169636	no	1
			47af3b9110014f303c7cf913d9ddb8e283a7e6d3		
Warnings:					
Information:					
27	NPL Documents	Medline_abstract_DEZUBE_2000.pdf	164570	no	1
			281f96252995415006a257d1658a5ab7ea8a2e5d		
Warnings:					
Information:					
28	NPL Documents	Medline_abstract_ZANUSSI_1996.pdf	164062	no	1
			d224f9eca937ee886df5554a2fad365db9aa9d8		
Warnings:					
Information:					

29	NPL Documents	MEDSTRAND_Characterization_novel_1993.pdf	2102893	no	10
			6f271dbb46057b96148af3324e4a5a4cd5ab25c8		
Warnings:					
Information:					
30	NPL Documents	MEHIGAN_Changes_TCELL_subsets_2001.pdf	389631	no	5
			30838b2c1c1f42dd5b81c60cf6117bf795ff2a18		
Warnings:					
Information:					
31	NPL Documents	MILLER_Human_immunodeficiency_2000.pdf	119454	no	9
			e73f490e0037fa1c481900e7b19b0355a7fdc1c5		
Warnings:					
Information:					
32	NPL Documents	MIYAZONO_Surgical_Maneuvers_Enhance_Molecular_2001.pdf	495721	no	6
			66b13954dd6e437e8296def8cac1b6ffdadf9b3		
Warnings:					
Information:					
33	NPL Documents	MONSONEGO_Immunotherapeutic_2003.pdf	840481	no	6
			5431fb4aea1f62708583ca6a041da85beff743fc		
Warnings:					
Information:					
34	NPL Documents	MOORE_Genetic_subtypes_2001.pdf	103140	no	9
			de10ffc19d9d29d7266ec1caab3c7acd02e96154		
Warnings:					
Information:					
35	NPL Documents	MORGAN_CD25_Cell_2003.pdf	818891	no	9
			2456c474fb1f1e3bc0cefb43f3578a93e5b6533f		
Warnings:					
Information:					
36	NPL Documents	MORSE_Retrovirus_induced_1992.pdf	1992192	no	15
			b4186c9dad58cde3788cd26e6fbd6989cfc44d8c		
Warnings:					
Information:					
37	NPL Documents	MORTENSEN_C-Reactive_protein_inflammation_2001.pdf	1470037	no	14
			d8dd1e1b0def46c68abf02ff040147ea73b76df4		
Warnings:					
Information:					

38	NPL Documents	MURPHY_New_strategies_preventing_1999.pdf	918302	no	7
			c2efa9465b5fb23381fdc1798054c7cb84b24e0d		
Warnings:					
Information:					
39	NPL Documents	NASTI_Risk_benefit_assessment_treatment.pdf	3487453	no	24
			29f748eaff56daf554a28bc4e6bca464a308583c		
Warnings:					
Information:					
40	NPL Documents	ORENSTEIN_Looking_Beyond_highly_active2.pdf	2621956	no	11
			415ada4480148868f00e44240f8531294c577f4e		
Warnings:					
Information:					
41	NPL Documents	ORTIZ_HIV1_Specific_immune.pdf	265612	no	6
			2f2c4f816bba44527e0b02ee11d41dd9cd0d5941		
Warnings:					
Information:					
42	NPL Documents	PEPYS_Creative_protein_2003.pdf	1119660	no	8
			b1843f652a65ec1ef43933c73b984c279b2fd1d3		
Warnings:					
Information:					
43	NPL Documents	RACKE_Intravenous_antigen_1996.pdf	1590227	no	11
			3d712fc4afa3fef77a74c5d8d6bcd30deb5cb49e		
Warnings:					
Information:					
44	NPL Documents	RAKOWICZ_Human_immunodeficiency_virus.pdf	1074590	no	9
			1757072ef0162093cf6965800294fa582be95984		
Warnings:					
Information:					
45	NPL Documents	RAKOWICZ_Relevance_of_Viral_RAK.pdf	178491	no	6
			1b5c97f8c4c16e8e6c91ba405666216572f8e4c1		
Warnings:					
Information:					
46	NPL Documents	READ_CD4_Regulatory_2001.pdf	920707	no	6
			f553f6bc4577f0935bb6d2ed701c0797303a83ac		
Warnings:					
Information:					

47	NPL Documents	ROSSI_Inhibition_murine_aids.pdf	2171548	no	10
			3ae587032885b0d9ad406c700f5f15a519c961eb		
Warnings:					
Information:					
48	NPL Documents	ROUSE_Regulatory_tcells_2006.pdf	1857789	no	15
			cf104b3fe06fda52bad05ceba53ad06a3468c4f4		
Warnings:					
Information:					
49	NPL Documents	SAHNI_HIV_2004_.pdf	1428607	no	8
			6b9b56e42725506caef7104a9a65dbf123e64af0		
Warnings:					
Information:					
50	NPL Documents	SAKAGUCHI_Regulatory_tcells_2000.pdf	498959	no	4
			d9c7811038644f12972604dc6a23fb2a899439f		
Warnings:					
Information:					
51	NPL Documents	SANTAMARIA_B7CD28_Costimulation_2000.pdf	641562	no	7
			870e124cf2c66ab396e378280a8b0f040311641d		
Warnings:					
Information:					
52	NPL Documents	SHEPHERD_Combination_chemotherapy.pdf	1317063	no	5
			2bb0f6fa6353c3ab83397edc62690055a07586b1		
Warnings:					
Information:					
53	NPL Documents	SHIH_Detection_multiple_1989.pdf	3091306	no	12
			176b83539db53f9425c8c9a668cb760c2683e1b1		
Warnings:					
Information:					
54	NPL Documents	SMITH_Use_two_dimensional_2001.pdf	1073412	no	7
			3d3bd1957ffe52117227b1cd3eccda615b4ce3a0		
Warnings:					
Information:					
55	NPL Documents	SPEISER_TNF_Receptor_1997.pdf	1280989	no	6
			833cc41ce4596a89e5b003c9d313a6c7c9b75280		
Warnings:					
Information:					

56	NPL Documents	STOTT_Candidate_vaccines_protect_1998.pdf	1002757	no	6
			1fd51f8f4d639eacc300ffba1dca902d97a92f61		
Warnings:					
Information:					
57	NPL Documents	SURIPAYER_CD4_CD5_Tcells_1998.pdf	855856	no	7
			ddcdb7ac76318df7d309c0a573e2f14fa27cd59fd		
Warnings:					
Information:					
58	NPL Documents	TAKAHASHI_Immunologic_self_1998_.pdf	1293185	no	12
			20abc69cd6b3f6591ca8b4eedf59513e0f95c299		
Warnings:					
Information:					
59	NPL Documents	TAN_Evaluation_natural_products_1991.pdf	1616042	no	12
			d2260562980ea7bbb7d8c3ede1dfcfc653468334		
Warnings:					
Information:					
60	NPL Documents	TAWA_Rhabdomyosarcoma_1982.pdf	607944	no	8
			fd213a899da2f8cce1accfb778b99dee8fe5cdad1		
Warnings:					
Information:					
Total Files Size (in bytes):			58711084		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					